DAFTAR PUSTAKA

Abouhamda, A., Alturkstani, M. and Jan, Y. (2019) 'Lower sensitivity of ankle-brachial index measurements among people suffering with diabetes-associated vascular disorders: A systematic review', *SAGE Open Medicine*, 7, p. 205031211983503. Available at: https://doi.org/10.1177/2050312119835038.

Aboyans, V. *et al.* (2018) '2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)', *European Heart Journal*, 39(9), pp. 763–816. Available at: https://doi.org/10.1093/eurheartj/ehx095.

Adamescu, E., Dobjanschi, C., & Popa, A. (2015) '"CORRELATIONS BETWEEN THE SEVERITY OF DIABETIC PERIPHERAL NEUROPATHY AND OTHER MICROVASCULAR COMPLICATIONS IN A GROUP OF PATIENS WITH DIABETES."'

Al-Ani, F., Al-Nimer, M. and Ali, F. (2011) 'Dyslipidemia as a contributory factor in etiopathogenesis of diabetic neuropathy', *Indian Journal of Endocrinology and Metabolism*, 15(2), p. 110. Available at: https://doi.org/10.4103/2230-8210.81940.

Allison, M.A. *et al.* (2008) 'A High Ankle-Brachial Index Is Associated With Increased Cardiovascular Disease Morbidity and Lower Quality of Life', *Journal of the American College of Cardiology*, 51(13), pp. 1292–1298. Available at: https://doi.org/10.1016/j.jacc.2007.11.064.

Al-Qaisi, M. (2009) 'Ankle Brachial Pressure Index (ABPI): An update for practitioners', *Vascular Health and Risk Management*, p. 833. Available at: https://doi.org/10.2147/VHRM.S6759.

Álvaro-Afonso, F.J. *et al.* (2018) 'Interobserver reliability of the ankle–brachial index, toe–brachial index and distal pulse palpation in patients with diabetes', *Diabetes and Vascular Disease Research*, 15(4), pp. 344–347. Available at: https://doi.org/10.1177/1479164118767599.

Baba M, Suzuki C, Tomiyama M, S. (2015) 'Staging system of diabetic neuropathy by the sural and tibial nerve conduction study.', *J Peripher Nerv Syst*, 20: 98.

Beldon, P (2010) 'Performing A Doppler Assesment: The Procedure. Wound Essentials', 5: 87-90.

Bilous, Rudy W, Richard Donnelly, Iskandar Idris (ed.) (2021) *Handbook of diabetes*. NJ : Wiley-Blackwell (Fifth edition).

Boulton, A.J. *et al.* (2005) 'The global burden of diabetic foot disease', *The Lancet*,

366(9498), pp. 1719–1724. Available at: https://doi.org/10.1016/S0140-6736(05)67698-2.

Bril, V. *et al.* (2009) 'Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy', *Diabetic Medicine*, 26(3), pp. 240–246. Available at: https://doi.org/10.1111/j.1464-5491.2009.02667.x.

C. E. Ekpenyong, U. Akpan, J. O. Ibu, and D. E. Nyebuk (2012) 'Gender and age specific prevalence and associated risk factors of type 2 Diabetes mellitus in Uyo metropolis, South Eastern Nigeria', *Diabetologia Croatica*, 41.

Cernea, S. and Raz, I. (2021a) 'Management of diabetic neuropathy', *Metabolism*, 123, p. 154867. Available at: https://doi.org/10.1016/j.metabol.2021.154867.

Cernea, S. and Raz, I. (2021b) 'Management of diabetic neuropathy', *Metabolism*, 123, p. 154867. Available at: https://doi.org/10.1016/j.metabol.2021.154867.

Chevtchouk, L., Silva, M.H.S. da and Nascimento, O.J.M. do (2017) 'Ankle-brachial index and diabetic neuropathy: study of 225 patients', *Arquivos de Neuro-Psiquiatria*, 75(8), pp. 533–538. Available at: https://doi.org/10.1590/0004-282x20170084.

Cho, Y.N. *et al.* (2014) 'The Role of Insulin Resistance in Diabetic Neuropathy in Koreans with Type 2 Diabetes Mellitus: A 6-Year Follow-Up Study', *Yonsei Medical Journal*, 55(3), p. 700. Available at: https://doi.org/10.3349/ymj.2014.55.3.700.

Clair, C. *et al.* (2015) 'The Effect of Cigarette Smoking on Diabetic Peripheral Neuropathy: A Systematic Review and Meta-Analysis', *Journal of General Internal Medicine*, 30(8), pp. 1193–1203. Available at: https://doi.org/10.1007/s11606-015-3354-y.

Dachun Xu *et al.* (2010) 'Sensitivity and specificity of the ankle—brachial index to diagnose peripheral artery disease: a structured review', *Vascular Medicine*, 15(5), pp. 361–369. Available at: https://doi.org/10.1177/1358863X10378376.

Deli, G. *et al.* (2013) 'Diabetic Neuropathies: Diagnosis and Management', *Neuroendocrinology*, 98(4), pp. 267–280. Available at: https://doi.org/10.1159/000358728.

Farheen, A., Malipatil, B.S. and Arif, G. (2015) 'Nerve conduction in type 2 diabetics and its correlation with glycosylated haemoglobin', *Journal of Evolution of Medical and Dental Sciences*, 4(6), p. 1023+.

Feldman, E.L. *et al.* (2017) 'New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain', *Neuron*, 93(6), pp. 1296–1313. Available at: https://doi.org/10.1016/j.neuron.2017.02.005.

Galbat, E.A.E.A. *et al.* (2022) 'Is There A Relation Between Peripheral Nerves

Conduction Study and Cardiovascular Assessment in Men with Type 2 Diabetes Mellitus? (A Cross-Sectional Study)', *The Egyptian Journal of Hospital Medicine*, 89(2), pp. 7302–7308. Available at: https://doi.org/10.21608/ejhm.2022.274414.

H Sjahrir (2006) 'Diabetic Neuropathy:The Pathoneurobiology & Treatment Update', *USU Press. Medan* [Preprint].

Hamasaki, H. and Hamasaki, Y. (2017) 'Diabetic Neuropathy Evaluated by a Novel Device: Sural Nerve Conduction Is Associated with Glycemic Control and Ankle–Brachial Pressure Index in Japanese Patients with Diabetes', *Frontiers in Endocrinology*, 8, p. 203. Available at: https://doi.org/10.3389/fendo.2017.00203.

Hamid, W.S. *et al.* (2021) 'Nerve conduction and its correlations with duration of diabetes mellitus and glycosylated haemoglobin in type 2 diabetes mellitus (T2DM)', *Journal of Endocrinology, Metabolism and Diabetes of South Africa*, 26(2), pp. 46–51. Available at: https://doi.org/10.1080/16089677.2021.1877444.

Handfield, S. (2013) 'Formation of a Provincial Nursing Skin and Wound Committee', *Journal of Wound, Ostomy & Continence Nursing*, 40(6), pp. 568–571. Available at: https://doi.org/10.1097/01.WON.0000436433.92003.de.

Iwamoto, Y. *et al.* (2022) 'Correlation of Baba's diabetic neuropathy classification with various diabetes-related complications', *Frontiers in Endocrinology*, 13, p. 1054934. Available at: https://doi.org/10.3389/fendo.2022.1054934.

Jeličić Kadić, A. *et al.* (2014) 'Using the WHO Essential Medicines List to Assess the Appropriateness of Insurance Coverage Decisions: A Case Study of the Croatian National Medicine Reimbursement List', *PLoS ONE*. Edited by K. Bond, 9(10), p. e111474. Available at: https://doi.org/10.1371/journal.pone.0111474.

Kautzky-Willer, A., Harreiter, J. and Pacini, G. (2016) 'Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus', *Endocrine Reviews*, 37(3), pp. 278–316. Available at: https://doi.org/10.1210/er.2015-1137.

Kementrian Kesehatan Republik Indonesia (no date) 'Hasil Utama Riskesdas 2018', in. Website Departemen Kesehatan RI (online). Available at: http://www.depkes.go.id/resources /download/info-terkini/materi.rakorpop_2018/Hasil%20Riskerdas%202018.pdf. Published 2018. (Accessed: 10 July 2022).

Khawaja, N. *et al.* (2018) 'The prevalence and risk factors of peripheral neuropathy among patients with type 2 diabetes mellitus; the case of Jordan', *Diabetology & Metabolic Syndrome*, 10(1), p. 8. Available at: https://doi.org/10.1186/s13098-018-0309-6.

Kim, E.S. *et al.* (2011) 'Diabetic Peripheral Neuropathy Is Associated With Increased Arterial Stiffness Without Changes in Carotid Intima–Media Thickness in Type 2 Diabetes', *Diabetes Care*, 34(6), pp. 1403–1405. Available at: https://doi.org/10.2337/dc10-2222.

Kim, Y.A. *et al.* (2014) 'Prevalence and Risk Factors for the Peripheral Neuropathy in Patients with Peripheral Arterial Occlusive Disease', *Vascular Specialist International*, 30(4), pp. 125–132. Available at: https://doi.org/10.5758/vsi.2014.30.4.125.

Kisozi, T. *et al.* (2017) 'Prevalence, severity and factors associated with peripheral neuropathy among newly diagnosed diabetic patients attending Mulago hospital: a cross-sectional study', *African Health Sciences*, 17(2), p. 463. Available at: https://doi.org/10.4314/ahs.v17i2.21.

Liu, X. *et al.* (2019) 'The risk factors for diabetic peripheral neuropathy: A meta-analysis', *PLoS ONE*, 14(2), p. e0212574. Available at: https://doi.org/10.1371/journal.pone.0212574.

Miftahurachman Miftahurachman, Nushrotul Lailiyya, Handika Sonjaya Juhana, U.G. (2019) 'Correlation between Ankle-Brachial Index Score and Diabetic Polyneuropathy Degree of Severity', *Faculty of Medicine Universitas Padjadjaran*, 51 No. 3.

Mørkrid, K., Ali, L. and Hussain, A. (2010) 'Risk factors and prevalence of diabetic peripheral neuropathy: A study of type 2 diabetic outpatients in Bangladesh', *International Journal of Diabetes in Developing Countries*, 30(1), p. 11. Available at: https://doi.org/10.4103/0973-3930.60004.

Muthiah Hasnah Suri, Hasnawi Haddani, and Sadakata Sinulingga (2015) 'Hubungan Karakteristik, Hiperglikemi, dan Kerusakan Saraf Pasien Neuropati Diabetik di RSMH Palembang Periode 1 Januari 2013 Sampai dengan 30 November 2014', *Jurnal Kedokteran dan Kesehatan*, 2(3), pp. 305–310.

Papanas, N. and Ziegler, D. (2015a) 'Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015', *The Review of Diabetic Studies*, 12(1–2), pp. 48–62. Available at: https://doi.org/10.1900/RDS.2015.12.48.

Papanas, N. and Ziegler, D. (2015b) 'Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015', *The Review of Diabetic Studies : RDS*, 12(1–2), pp. 48–62. Available at: https://doi.org/10.1900/RDS.2015.12.48.

Pasnoor, M. *et al.* (2013) 'Diabetic Neuropathy Part 1', *Neurologic Clinics*, 31(2), pp. 425–445. Available at: https://doi.org/10.1016/j.ncl.2013.02.004.

PERKENI (2021) *Pedoman Petunjuk Praktis Terapi Insulin Pada Pasien Diabetes Melitus*. PB Perkeni.

Poernomo H, Basuki M. Widjaja D. (2003) *Petunjuk Praktis Elektrodiagnostik*.

Bagian Ilmu Penyakit Saraf. Surabaya: Fakultas Kedokteran Airlangga Airlangga University Press.

Ponirakis, G. *et al.* (2019) 'Prevalence and risk factors for painful diabetic neuropathy in secondary healthcare in Qatar', *Journal of Diabetes Investigation*, 10(6), pp. 1558–1564. Available at: https://doi.org/10.1111/jdi.13037.

Pop-Busui, R. *et al.* (2017) 'Diabetic Neuropathy: A Position Statement by the American Diabetes Association', *Diabetes Care*, 40(1), pp. 136–154. Available at: https://doi.org/10.2337/dc16-2042.

Potier, L. *et al.* (2011) 'Use and Utility of Ankle Brachial Index in Patients with Diabetes', *European Journal of Vascular and Endovascular Surgery*, 41(1), pp. 110–116. Available at: https://doi.org/10.1016/j.ejvs.2010.09.020.

Pradeepa, R. *et al.* (2008) 'Prevalence and risk factors for diabetic neuropathy in an urban south Indian population: the Chennai Urban Rural Epidemiology Study (CURES-55)', *Diabetic Medicine*, 25(4), pp. 407–412. Available at: https://doi.org/10.1111/j.1464-5491.2008.02397.x.

Preston, D.C. and Shapiro, B.E. (2021) *Electromyography and neuromuscular disorders: clinical-electrophysiologic-ultrasound correlations*. 4th edn. Philadelphia.: Elsevier.

Rahman T (2017) 'Gambaran Kejadian Status Neuropati Perifer pada Penyandang Diabetes Mellitus di Puskesmas Sukoharjo.'

REBECCA LOUISE BRANCH (2010) *PERIPHERAL NEUROPATHY IN HYPERTENSION*. School of Clinical & Experimental Medicine College of Medical & Dental Sciences, The University of Birmingham.

Rina, Henry S, Heri N, (2016) 'Faktor-Faktor Risiko Kejadian Kaki Diabetik pada Penderita Diabetes Melitus Tipe 2 (Studi Kasus Kontrol di RSUP dr. M. Djamil Padang).', *Jurnal Epidemiologi Kesehatan Komunitas*, 1, pp. 48–60.

Riyaz Mohammed (2014) 'A CLINICAL APPROACH TO DIABETIC PERIPHERAL NEUROPATHY', *Journal of Evidence based Medicine and Healthcare*, 1(16), pp. 2009-2016.

Sadosky, A. *et al.* (2015) 'Healthcare utilization and costs in diabetes relative to the clinical spectrum of painful diabetic peripheral neuropathy', *Journal of Diabetes and its Complications*, 29(2), pp. 212–217. Available at: https://doi.org/10.1016/j.jdiacomp.2014.10.013.

Saveleff, M.G., Callaghan, B.C. and Feldman, E.L. (2020) 'The emerging role of dyslipidemia in diabetic microvascular complications', *Current Opinion in Endocrinology, Diabetes & Obesity*, 27(2), pp. 115–123. Available at: https://doi.org/10.1097/MED.0000000000000533.

Smith, A.G. and Živković, S. (2020) 'The hidden costs of painful diabetic neuropathy revealed', *Neurology: Clinical Practice*, 10(1), pp. 3–4. Available at: https://doi.org/10.1212/CPJ.0000000000000759.

Stanford Medicine (2018) 'Measuring and Understanding the Ankle Brachial Index (ABI).' Available at: //stanfordmedicie25.stanford.edu/the25/ankle.html.

Subekti I. (2009) *Buku Ajar Ilmu Penyakit Dalam.* V. Jakarta: Fakultas Kedokteran Universitas (III).

Suvi Karuranga, Joao da Rocha Fernandes, Yadi Huang, Belma Malanda. (2017) *IDF DIABETES ATLAS*. Eighth edition. International Diabetes Federation.

Tamer, A. *et al.* (2006) 'The Prevalence of Neuropathy and Relationship with Risk Factors in Diabetic Patients: A Single-Center Experience', *Medical Principles and Practice*, 15(3), pp. 190–194. Available at: https://doi.org/10.1159/000092180.

Toth, P.P. *et al.* (2012) 'The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus', *Cardiovascular Diabetology*, 11(1), p. 109. Available at: https://doi.org/10.1186/1475-2840-11-109.

Ulfa Husnul Fata (2017) 'Overview of Ankle Brachial Index (ABI) Values on Diabetes Mellitus Type 2 in Blitar', *Jurnal Ners dan Kebidanan*, 4(3), pp. 254–259. Available at: https://doi.org/10.26699/jnk.v4i3.ART.

Verma, M. *et al.* (2018) 'Role of Ankle Brachial Index (ABI) in Management of Non-Healing Ulcers of Lower Limb', *Journal of Universal Surgery*, 06(01). Available at: https://doi.org/10.21767/2254-6758.100096.

Vincent, A.M. *et al.* (2009) 'Hyperlipidemia: a new therapeutic target for diabetic neuropathy', *Journal of the Peripheral Nervous System*, 14(4), pp. 257–267. Available at: https://doi.org/10.1111/j.1529-8027.2009.00237.x.

Vlassara, H. and Uribarri, J. (2014) 'Advanced Glycation End Products (AGE) and Diabetes: Cause, Effect, or Both?', *Current Diabetes Reports*, 14(1), p. 453. Available at: https://doi.org/10.1007/s11892-013-0453-1.

Xu, L. *et al.* (2019) 'The value of ankle-branchial index screening for cardiovascular disease in type 2 diabetes', *Diabetes/Metabolism Research and Reviews*, 35(1), p. e3076. Available at: https://doi.org/10.1002/dmrr.3076.

Yagihashi, S., Mizukami, H. and Sugimoto, K. (2011) 'Mechanism of diabetic neuropathy: Where are we now and where to go?: Diabetic neuropathy and its mechanism', *Journal of Diabetes Investigation*, 2(1), pp. 18–32. Available at: https://doi.org/10.1111/j.2040-1124.2010.00070.x.

Yokoyama, H. *et al.* (2007) 'Diabetic neuropathy is closely associated with arterial stiffening and thickness in Type 2 diabetes', *Diabetic Medicine*, 24(12), pp. 1329–1335. Available at: https://doi.org/10.1111/j.1464-5491.2007.02278.x.

Yovera-Aldana, M. *et al.* (2021) 'Prevalence and incidence of diabetic peripheral neuropathy in Latin America and the Caribbean: A systematic review and meta-analysis', *PLOS ONE*. Edited by A. Negida, 16(5), p. e0251642. Available at: https://doi.org/10.1371/journal.pone.0251642.

Ziegler, D. *et al.* (2008) 'Prevalence of Polyneuropathy in Pre-Diabetes and Diabetes Is Associated With Abdominal Obesity and Macroangiopathy', *Diabetes Care*, 31(3), pp. 464–469. Available at: https://doi.org/10.2337/dc07-1796.

Zychowska, M. *et al.* (2013) 'Mechanisms and pharmacology of diabetic neuropathy – experimental and clinical studies', *Pharmacological Reports*, 65(6), pp. 1601–1610. Available at: https://doi.org/10.1016/S1734-1140(13)71521-4.

Lampiran 1. Rekomendasi Persetujuan Etik

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari.,MMed,PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK
Nomor : 87/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 3 Februari 2023

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH23010044		No Sponsor Protokol	
Peneliti Utama	**dr. Fiddya Putri**		Sponsor	
Judul Peneliti	Hubungan Antara Ankle Brachial Index (ABI) Dengan Derajat Keparahan Neuropati Diabetik Pada Pasien Diabetes Melitus Tipe 2			
No Versi Protokol	**2**		Tanggal Versi	**2 Februari 2023**
No Versi PSP	**2**		Tanggal Versi	**2 Februari 2023**
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo Makassar			
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal		Masa Berlaku **3 Februari 2023** sampai **3 Februari 2024**	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)**		Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)**		Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 2. FORMULIR PERSETUJUAN SETELAH PENJELASAN

Saya yang bertandatangan di bawah ini:

Nama   : ....

Umur   : ....

Alamat   : ....

No. HP   : ....

Telah mendengar/membaca dan mengerti penjelasan yang diberikan mengenai tujuan, manfaat, dan prosedur pada penelitian dengan judul Hubungan Antara Ankle Brachial index (ABI) dengan Derajat Keparahan Neuropati Diabetik pada pasien diabetes melitus. Saya menyatakan setuju untuk ikut dalam penelitian ini secara sukarela tanpa paksaan.

Saya tahu bahwa keikutsertaan saya ini bersifat sukarela tanpa paksaan, sehingga saya bisa menolak ikut atau mengundurkan diri dari penelitian ini. Saya berhak bertanya atau meminta penjelasan pada peneliti bila masih ada hal yang belum jelas atau masih ada hal yang ingin saya ketahui tentang penelitian ini.

Saya juga mengerti bahwa semua biaya yang dikeluarkan sehubungan dengan penelitian ini akan ditanggung oleh peneliti. Saya percaya bahwa keamanan dan kerahasiaan data penelitian terjamin dan dengan ini menyetujui semua data yang dihasilkan pada penelitian ini untuk disajikan dalam bentuk lisan maupun tulisan.

Dengan membubuhkan tanda tangan saya di bawah ini, saya menegaskan keikutsertaan saya secara sukarela dalam studi penelitian ini.

	Nama	Tanda tangan	Tgl/Bln/Thn
Responden	....	....	....
Saksi 1	....	....	....
Saksi 2	....	....	....

Penanggung jawab penelitian :

Nama   : dr. Fiddya Putri

Alamat   : Nusa Tamalanrea Indah Jl. Akasia Blok C1, Makassar

Telepon (HP) : 081255010575

Penanggungjawab medis :

Nama   : Dr. dr. Audry Devisanty Wuysang, Sp.S (K), M.Si

Alamat (RS) : Jl. G. Salahutu No. 24, Makassar

Telepon(HP) : 08152529593

Lampiran 3. FORMULIR PASIEN PENELITIAN
NO. ………..

Tgl Pemeriksaan		Pemeriksa		Jam	
Identitas Pasien					
Nomor Rekam Medis			RS		
Nama					
Umur/ Tanggal lahir		tahun/ - - (*dd – mm – yyyy*)			
Alamat / No telepon					
Jenis kelamin		L/P	Pendidikan terakhir		
Biometrik		TB = cm; BB = kg; IMT = kg/m^2			
Pekerjaan					
Tipe DM		1/2			
Durasi DM		tahun			
Berobat DM teratur		Ya/Tidak			
Tatalaksana DM		OAD/insulin/OAD + insulin			
Hipertensi		Ya/Tidak			
Dislipidemia		Ya/Tidak			
Riw merokok 1 thn terakhir		Ya/Tidak			
HbA1c					

Kriteria Inklusi		
Pertanyaan	**Ya**	**Tdk**
1. Pasien dengan diagnosis DM sesuai kriteria *American Diabetes Association*		
2. Pasien berusia antara 25-65 tahun		
3. Pasien kooperatif, bersedia diikutsertakan dalam penelitian ini dan menandatangani informed consent.		
Kriteria Eksklusi		
Pertanyaan	**Ya**	**Tdk**
1. Pasien dengan gangguan kesadaran, penyakit cerebrovascular dan kanker		
2. Penderita penyakit ginjal kronis, penyakit hati kronis, penyakit keganasan dan HIV		
3. Pasien yang sedang menjalani kemoterapi atau radioterapi		

Lampiran 4. FORMULIR NCS (*NERVE CONDUCTION STUDIES*)

Indikator	Kanan	Kiri	Nilai Normal
Tibialis (motorik)			
Latensi distal (ms)			≤5,8
Amplitudo (mV)			≥4,0
NCV* (m/s)			≥41
Peroneus (motorik)			
Latensi distal (ms)			≤6,5
Amplitudo (mV)			≥2,0
NCV* (m/s)			≥44
Suralis (sensorik)			
Latensi puncak (ms)			≤4,4
Amplitudo (μV)			≥6
NCV* (m/s)			≥40
Peroneus superficialis (sensorik)			
Latensi puncak (ms)			≤4,4
Amplitudo (μV)			≥6
NCV* (m/s)			≥40

*NCV: *Nerve Conduction Velocity*

Kategori

Tipe neuropati berdasarkan jenis saraf : Motorik/sensorik/sensorimotor
Tipe neuropati berdasarkan patogenesis : Demielinasi/aksonal/campuran
BDC : 0/1/2/3/4

Lampiran 5. FORMULIR ABI (*ANKLE BRACHIAL INDEX)*

Tekanan Darah	Kanan	Kiri
Tangan		
Sistole		
Diastole		
Kaki		
Sistole		
Diastole		
Nilai ABI		
Kategori		

Interpretasi

    a. Kalsifikasi   = >1,3

    b. Normal   = 0,91 – 1,3

    c. Oklusi ringan   = 0,70 – 0,90

    d. Oklusi sedang   = 0,40 – 0,69

    e. Oklusi berat   = < 0,40

Lampiran 6. Raw Data Penelitian

No	Nama	Tgl Lahir	Umur	Jenis Kelamin	Pend Terakhir	TB	BB	IMT	Terapi DM	HT	Dislipid	Merokok	HbA1c	BDC	ABI Kanan	ABI Kiri	ABI Kanan	ABI Kiri
1	St	25/05/65	57	Perempuan	D3	149	63	28,38	Insulin	Ya	Ya	Tidak	14	Normal	1	1	Boderline	Boderline
2	Ha	31-Dec-64	57	Perempuan	S1	153,00	52,60	22,47	OAD + insulin	Tidak	Ya	Tidak	11,3	Sedang	0,9	0,8	Oklusi ringan	Oklusi ringan
3	Sy	1-Jan-65	57	Laki-laki	SMA	160	49	19,14	OAD + insulin	Tidak	Tidak	Tidak	6,7	Ringan	0,9	1	Oklusi ringan	Boderline
4	In	13/11/66	56	Perempuan	SMA	160	56	21,88	OAD	Ya	Ya	Tidak	6,1	Normal	1,2	1,1	Normal	Normal
5	Ik	19-Aug-84	38	Laki-laki	S1	168,00	70,00	24,80	OAD	Ya	Ya	Tidak	8,2	Normal	1	1	Boderline	Boderline
6	Ka	11-Jan-78	44	Perempuan	SMA	153	65	27,77	OAD	Ya	Ya	Tidak	8,2	Normal	1	1,1	Boderline	Normal
7	An	31-Dec-60	61	Laki-laki	S2	169,00	67,00	23,46	OAD	Tidak	Tidak	Tidak	10,8	Ringan	0,9	1	Oklusi ringan	Boderline
8	Mu	26/11/64	58	Perempuan	S3	155	67	27,89	OAD	Ya	Ya	Tidak	10,4	Sedang	1	1	Boderline	Boderline
9	Da	7-Sep-69	53	Laki-laki	SLTP	162,50	61,50	23,29	OAD	Tidak	Tidak	Ya	7,9	Sedang	1	1	Boderline	Boderline
10	Ma	18/03/75	47	Perempuan	SMA	158	57	22,83	OAD	Tidak	Tidak	Tidak	7,8	Ringan	0,9	1	Oklusi ringan	Boderline
11	Moe	4-Feb-55	64	Laki-laki	S1	157,00	71,00	28,80	OAD	Ya	Ya	Ya	7,9	Ringan	0,8	1	Oklusi ringan	Boderline
12	Her	10/10/65	57	Perempuan	S1	160,00	60,00	23,44	OAD	Tidak	Ya	Tidak	12	Normal	0,8	0,8	Oklusi ringan	Oklusi ringan
13	Na	31/12/68	53	Perempuan	S1	149,00	37,00	16,67	OAD	Ya	Tidak	Tidak	7,3	Normal	1	1,1	Boderline	Normal
14	Muh	26-May-75	47	Laki-laki	S2	166,50	72,50	26,15	Insulin	Tidak	Ya	Tidak	14,3	Sedang	1	1	Boderline	Boderline
15	Ra	18-Jun-56	66	Laki-laki	S2	162,50	55,50	21,02	Insulin	Tidak	Tidak	Ya	10,5	Ringan	1,2	1	Normal	Boderline
16	HS	2-Aug-68	54	Perempuan	SLTA	160,00	65,00	25,39	Insulin	Ya	Tidak	Tidak	9,7	Sedang	0,8	0,9	Oklusi ringan	Oklusi ringan
17	AS	15/08/63	59	Laki-laki	SLTA	176,00	56,00	18,08	Insulin	Tidak	Tidak	Tidak	9,8	Normal	1	1	Boderline	Boderline
18	Hu	25/05/61	61	Laki-laki	SLTA	156,00	76,00	31,23	OAD	Ya	Tidak	ya	11,28	Sedang	0,7	0,6	Oklusi ringan	Oklusi ringan
19	FM	24/12/60	62	Perempuan	SD	160,00	75,00	29,30	OAD	Ya	Tidak	Tidak	11,5	Sedang	1	1	Boderline	Boderline
20	Hw	04/04/63	59	Perempuan	SLTA	154,00	60,00	25,30	OAD	Tidak	Tidak	Tidak	8,2	Normal	1	1	Boderline	Boderline
21	Naz	18/03/58	64	Laki-laki	SLTA	160,00	65,00	25,39	OAD	Ya	Tidak	Tidak	8	Normal	0,9	0,8	Oklusi ringan	Oklusi ringan
22	Mah	17-Jun-69	53	Laki-laki	S1	162,00	52,00	19,81	Insulin	Tidak	Ya	Tidak	7,2	Sedang	1	1	Boderline	Boderline
23	Has	15/04/78	44	Perempuan	SD	143,50	55,50	26,95	OAD	Tidak	Tidak	Tidak	7,8	Normal	0,9	1	Oklusi ringan	Boderline
24	RS	30/04/69	53	Perempuan	S1	139,00	39,00	20,19	Insulin	Ya	Ya	Tidak	13	Ringan	1	1	Boderline	Boderline
25	Si	22/11/65	57	Laki-laki	SLTA	170,00	74,00	25,61	OAD	Tidak	Ya	Tidak	6,6	Normal	0,9	0,8	Oklusi ringan	Oklusi ringan
26	Hf	05/05/59	64	Laki-laki	S2	170,00	73,00	25,26	Insulin	Ya	Ya	Tidak	6,5	Sedang	1,1	1,1	Normal	Normal
27	FR	05/01/00	53	Perempuan	S2	160,00	56,00	21,88	Insulin + OAD	Tidak	Tidak	Tidak	10,1	Berat	1,4	1,4	Kalsifikasi	Kalsifikasi
28	RA	20-Dec-71	51	Laki-laki	S1	164,00	68,00	25,28	OAD + insulin	Ya	Ya	Ya	7,5	Sedang	1	1	Boderline	Boderline
29	Ts	20-Jun-73	49	Laki-laki	SLTA	150,00	41,00	18,22	OAD	Tidak	Tidak	Tidak	11,3	Berat	1,4	1,4	Kalsifikasi	Kalsifikasi

30	HMY	16-Dec-64	58	Laki-laki	S2	164,50	63,00	23,28	Insulin	Ya	Tidak	Ya	9,5	Berat	1	1	Boderline	Boderline
31	Ro	29-Jan-61	62	Perempuan	SLTA	155,50	66,00	27,30	OAD + insulin	Ya	Ya	Tidak	10,0	Sedang	0,8	0,9	Oklusi ringan	Oklusi ringan
32	Be	17-Sep-79	43	Perempuan	S1	159,50	72,00	28,30	Insulin	Tidak	Ya	Tidak	11,5	Sedang	0,8	0,9	Oklusi ringan	Oklusi ringan
33	Mmp	26-Mar-70	53	Perempuan	S1	151,00	48,00	21,05	Insulin	Tidak	Ya	Tidak	6,7	Sedang	0,8	0,9	Oklusi ringan	Oklusi ringan
34	Asf	20-Sep-75	47	Perempuan	S1	155,50	56,50	23,37	OAD	Tidak	Tidak	Tidak	10,6	Normal	1	1	Boderline	Boderline
35	Dl	7-Sep-69	53	Laki-laki	SLTP	162,50	61,50	23,29	OAD	Tidak	Tidak	Ya	7,9	Sedang	1	1	Boderline	Boderline
36	Wnh	28-Feb-66	57	Laki-laki	S3	160,00	70,00	27,34	Insulin	Tidak	Ya	Tidak	9,2	Sedang	1	1	Boderline	Boderline

Lampiran 7. Hasil Analisis Data Statistik

Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
ABI_Kanan * BDC	36	100.0%	0	0.0%	36	100.0%

ABI_Kanan * BDC Crosstabulation

Count

		BDC				Total
		Normal	Ringan	Sedang	Berat	
ABI_Kanan	Oklusi ringan	3	0	6	0	9
	Borderline	6	6	8	1	21
	Normal	3	0	1	0	4
	Kalsifikasi	0	0	0	2	2
Total		12	6	15	3	36

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	31.264a	9	.000
Likelihood Ratio	21.489	9	.011
Linear-by-Linear Association	.480	1	.489
N of Valid Cases	36		

a. 14 cells (87.5%) have expected count less than 5. The minimum expected count is .17.

Symmetric Measures

		Value	Approximate Significance
Nominal by Nominal	Contingency Coefficient	.682	.000
N of Valid Cases		36	

Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
ABI_Kiri * BDC	36	100.0%	0	0.0%	36	100.0%

ABI_Kiri * BDC Crosstabulation

Count

		BDC				Total
		Normal	Ringan	Sedang	Berat	
ABI_Kiri	Oklusi ringan	4	4	6	0	14
	Borderline	7	1	8	1	17
	Normal	1	1	1	0	3
	Kalsifikasi	0	0	0	2	2
Total		12	6	15	3	36

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	26.998[a]	9	.001
Likelihood Ratio	16.422	9	.059
Linear-by-Linear Association	2.420	1	.120
N of Valid Cases	36		

a. 13 cells (81.3%) have expected count less than 5. The minimum expected count is .17.

Symmetric Measures

		Value	Approximate Significance
Nominal by Nominal	Contingency Coefficient	.655	.001
N of Valid Cases		36	